Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.11 is 45% above its 5-year average of 0.07, near the high end of its 5-year range (0.00–0.11).
As of the fiscal period ended Tuesday, June 30, 2026. 5.45% above its 12-month average of 0.10.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.11.
DEBT TO EQUITY RATIO
0.11
DEBT TO EQUITY RATIO AVG TTM
0.10
DEBT TO EQUITY RATIO AVG 3Y
0.09
DEBT TO EQUITY RATIO AVG 5Y
0.07
DEBT TO EQUITY RATIO AVG 10Y
0.14
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+5.45%
CURRENT VS 3Y AVG
+21.16%
CURRENT VS 5Y AVG
+45.09%
CURRENT VS 10Y AVG
-23.26%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.12
median of 639 covered companies
CURRENT VS SECTOR MEDIAN
-9.44%
vs the sector median at left
Market Cap
$114.31M
Debt to Equity Ratio
N/A
TTM Avg
0.12
3Y Avg
0.14
5Y Avg
0.21
Market Cap
$115.04M
Debt to Equity Ratio
2.28
TTM Avg
3.15
3Y Avg
2.13
5Y Avg
1.28
Market Cap
$116.06M
Debt to Equity Ratio
N/A
TTM Avg
230.24
3Y Avg
153.68
5Y Avg
153.68
Market Cap
$111.61M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$116.80M
Debt to Equity Ratio
0.15
TTM Avg
0.11
3Y Avg
0.12
5Y Avg
0.12
Market Cap
$117.03M
Debt to Equity Ratio
0.27
TTM Avg
0.16
3Y Avg
0.12
5Y Avg
0.10
Market Cap
$117.29M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MaxCyte, Inc. (MXCT) | $114.08M | 0.11 | 0.10 | 0.09 | 0.07 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $114.31M | N/A | 0.12 | 0.14 | 0.21 |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.04M | 2.28 | 3.15 | 2.13 | 1.28 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.06M | N/A | 230.24 | 153.68 | 153.68 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.61M | 0.01 | 0.00 | 0.00 | 0.00 |
| Genelux Corporation (GNLX)vs › | $116.80M | 0.15 | 0.11 | 0.12 | 0.12 |
| BGM Group Ltd. (BGM)vs › | $111.27M | 0.00 | 0.00 | 0.01 | 0.08 |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | 0.27 | 0.16 | 0.12 | 0.10 |
| Coya Therapeutics, Inc. (COYA)vs › | $117.29M | 0.00 | 0.00 | 0.00 | 0.00 |
| Immunic, Inc. (IMUX)vs › | $110.74M | 0.00 | 0.05 | 0.03 | 0.02 |
Debt/Equity
0.11
Current Ratio
12.26
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.11 |
| 2026-03-31 | 0.10 |
| 2025-12-31 | 0.10 |
| 2025-09-30 | 0.10 |
| 2025-06-30 | 0.10 |
| 2025-03-31 | 0.09 |
| 2024-12-31 | 0.09 |
| 2024-09-30 | 0.09 |
| 2024-06-30 | 0.08 |
| 2024-03-31 | 0.08 |
| 2023-12-31 | 0.08 |
| 2023-09-30 | 0.07 |
| 2023-06-30 | 0.07 |
| 2023-03-31 | 0.07 |
| 2022-12-31 | 0.06 |
| 2022-09-30 | 0.06 |
| 2022-06-30 | 0.06 |
| 2022-03-31 | 0.05 |
| 2021-12-31 | 0.02 |
| 2021-09-30 | 0.00 |
| 2021-06-30 | 0.02 |
| 2021-03-31 | 0.02 |
| 2020-12-31 | 0.21 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.19 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.53 |
| 2019-09-30 | 0.53 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 0.41 |
| 2018-09-30 | 0.41 |
| 2018-06-30 | 0.33 |
| 2018-03-31 | 0.33 |
| 2017-12-31 | 0.26 |
| 2017-09-30 | 0.26 |
| 2017-06-30 | 0.20 |
| 2017-03-31 | 0.20 |
| 2016-12-31 | 0.98 |
| 2016-09-30 | 0.98 |
| 2016-06-30 | 0.71 |
| 2016-03-31 | 0.70 |
| 2015-12-31 | -1.64 |
| 2015-09-30 | -1.68 |
| 2015-06-30 | 0.59 |
| 2015-03-31 | -2.04 |
| 2014-12-31 | -2.98 |
| 2014-09-30 | -3.19 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
